LOAD MORE
You're viewed 18 of 19 products
Brexpiprazole
References
FAQ's
References
- Yamashita, Hiroshi; Matsubara, Jun; Oshima, Kunio; Kuroda, Hideaki; Ito, Nobuaki; Miyamura, Shin; Shimizu, Satoshi; Tanaka, Tatsuyoshi; Oshiro, Yasuo; Shimada, Jun; et al, Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders, Otsuka Pharmaceutical Co., Ltd., Japan, EP1869025B1, January 26, 2011
- Bhawar, H. S.; Sanket, Thete; Shinde, G. S., Development and validation of stability indicating RP-HPLC method for estimation of Brexpiprazole from bulk and tablet form, Journal of Drug Delivery and Therapeutics, Volume: 9, Issue: 4, Pages: 141-145, 2019
Frequently Asked Questions
What are the methods for controlling Brexpiprazole impurities?
The methods for controlling Brexpiprazole impurities include optimizing the synthetic process, using high-quality raw materials, employing effective purification methods, and implementing analytical methods to detect and quantify impurities.
How does the presence of impurities affect the shelf life of Brexpiprazole?
The presence of impurities in Brexpiprazole can reduce its shelf life and stability, leading to a shorter expiration date.
How are Brexpiprazole impurities detected?
Impurities in Brexpiprazole are typically detected using analytical techniques such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS).
What are the temperature conditions required to store Brexpiprazole impurities?
Brexpiprazole impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.